BRANFORD, Conn. & TORONTO--(BUSINESS WIRE)--Don Very, Ph.D., Vice President, Research of IBA today announced that IBA’s Assay Development Laboratory is now offering customers enhanced assay development services with the recent acquisition of a dotLab® System – an enabling platform for the development and deployment of assays. “Partnering with IBA is a logical next step for Axela as we continue to expand the breadth and depth of products that add value to researchers conducting protein discovery and clinical diagnostic research,” commented Rocky Ganske, President and CEO of Axela Inc.
dotLab System customers in the pharmaceutical, biotech and diagnostic industries can now augment internal biomarker programs with IBA’s contract assay development expertise for single or multiplexed immunoassay development.
In addition to custom assay development, IBA is partnering with Axela to expand the menu of biomarker assays optimized for use with the dotLab platform and the soon to be available panelPlusTM Sensors. Axela’s new real-time sensor technology offers customers freedom to combine preconfigured assays with their novel markers to accelerate biomarker validation.
The dotLab System’s novel technology for performing immunoassays and real-time study of protein interactions has demonstrated enhanced performance in many application areas including cardiology, oncology, and infectious disease. Benefits include extended dynamic range, simultaneous measurement of high and low abundance markers and concurrent detection of secondary information such as binding partners, isotype and avidity.
IBA is a privately held biotechnology company whose mission is the delivery of customized bioanalytical method development and sample analysis services to its global client base. IBA can enhance the discovery and development of new drug targets through its expertise in proteomics, biomarker development and bioanalytical method performance qualification.
About Axela Inc.
Axela’s products provide researchers with tools and reagents to study interactions, expand the utility of traditional immunoassays, and access unique categories of diagnostic markers. Axela is privately held with operations in Toronto and California. Axela’s major investor is VenGrowth Private Equity Partners Inc.
Mr. Charles Sloan, Director of Project Development
Mr. Paul Smith, VP Sales and Business Planning